Can-Fite Biopharma Ltd. ADR Annual stock financials by MarketWatch. View the latest CANF financial statements, income statements and financial ratios.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The average one-year price target for Can-Fite BioPharma - Depositary Receipt (NYSEAM:CANF) has been revised to $3.46 / share. This is a decrease of 17.42% from the prior estimate of $4.19 dated ...

$5.0 million upfront with up to an additional $10.0 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants RAMAT GAN, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

Can Fite Biofarma (CANF) is scheduled to report earnings on February 3, 2026. The last reported earnings were for reported on April 14, 2025 for FY. The Actual Revenue was $674K, which beat the ...

Can-Fite BioPharma ( (CANF)) has provided an update. On December 16, 2025, Can-Fite BioPharma Ltd. provided an update on its clinical and financial status. The company is actively enrolling patients ...

Multiple countries are approving Can-Fite BioPharma Ltd. CANF CFBI ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to ...